Service Description

$100 This innovative treatment is designed to assist individuals in managing their appetite, leading to effective weight loss outcomes. The method incorporates a glucagon-like peptide-1 (GLP-1) agonist, specifically semaglutide, which has been shown to lower glycated hemoglobin (A1C) levels, a key indicator of long-term blood glucose control. With a starting dosage of 0.25 mg and the potential to increase up to 2.5 mg of semaglutide, patients can experience a significant reduction in body fat and appetite.